Sarepta Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Great, everybody. We're going to get going with the next session. I'm Matthew Harrison, one of the Biotech Analysts here at Morgan Stanley. Very pleased to have Doug Ingram, the CEO of Sarepta with me for the next session. Just briefly before we get started, I have to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. Doug has promised that he is going to read the FDA communication for us. That will entail the entire session. No, sorry.
Questions & Answers
So Doug, I mean, I guess, look, maybe the first place to start is you've obviously had a bunch of back and forth. I think you've been public about sort of the commentary. I guess, maybe just walk us through what the rest of the fall looks like leading up
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
